Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer

  • Authors:
    • Josefa Salgado
    • Natalia Zabalegui
    • Carmen Gil
    • Ignacio Monreal
    • Javier Rodríguez
    • Jesús García-Foncillas
  • View Affiliations

  • Published online on: February 1, 2007     https://doi.org/10.3892/or.17.2.325
  • Pages: 325-328
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Pharmacogenetics is an increasingly useful field where the genetic studies are becoming an important tool for predicting drug toxicity and/or efficacy. Thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) gene polymorphisms could be highly informative tools in the clinical handling of colorectal cancer patients, who are following fluoropyrimidine based chemotherapy. Fifty-eight patients, with non-resectable metastatic colorectal cancer, were treated with capecitabine and raltitrexed, every three weeks. Patients were divided in a good-response group (complete and partial response) and a poor-response group (stable and progression). A genotype panel TS-DPD was evaluated. Results show that TS genotype analysis clearly differentiates patients with a worst response to a 5-fluorouracil based chemotherapy. DPD genotype was shown to be highly informative for prediction of toxicity of the treatment. These polymorphisms could represent an accurate, rapid and effective determination panel, indicative of resistance and toxicity for patients undergoing fluoropyrimidine based treatment.

Related Articles

Journal Cover

February 2007
Volume 17 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Salgado J, Zabalegui N, Gil C, Monreal I, Rodríguez J and García-Foncillas J: Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer. Oncol Rep 17: 325-328, 2007
APA
Salgado, J., Zabalegui, N., Gil, C., Monreal, I., Rodríguez, J., & García-Foncillas, J. (2007). Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer. Oncology Reports, 17, 325-328. https://doi.org/10.3892/or.17.2.325
MLA
Salgado, J., Zabalegui, N., Gil, C., Monreal, I., Rodríguez, J., García-Foncillas, J."Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer". Oncology Reports 17.2 (2007): 325-328.
Chicago
Salgado, J., Zabalegui, N., Gil, C., Monreal, I., Rodríguez, J., García-Foncillas, J."Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer". Oncology Reports 17, no. 2 (2007): 325-328. https://doi.org/10.3892/or.17.2.325